Session Details

S054 Pearls: Diagnostic and Therapeutic

Mon, Mar 10, 9:00 AM - 12:00 PM
Valencia Ballroom B
3 CME Available Symposium
View Map

DESCRIPTION

Faculty will share innovative approaches to a variety of common and perhaps less common conditions. We will present a number of new cases, new diagnostic approaches, surgical pearls, perhaps some older and forgotten approaches to frustrating conditions, aspects of regenerative medicine, and especially, off-label recommendations. Attendees are encouraged to email challenging cases or favorite off-label pearls to drspstone@gmail.com for inclusion in our discussions.

LEARNING OBJECTIVES

1.

Use innovative therapies for patients with complicated conditions, or common maladies unresponsive to commonly effective approaches.

2.

Safely and effectively utilize established medications for off label uses.

3.

Diagnose lesions with dermoscopy and appropriately communicate with the pathologist.

SCHEDULE

9:00 AM

Introduction

Stephen P. Stone, MD, FAAD

9:05 AM

Clinicopathologic Pearls

Morgan Wilson, MD, FAAD

9:40 AM

Therapeutic and Diagnostic Pearls

Mark Lebwohl, MD, FAAD

10:15 AM

Procedural Pearls

Rebecca Jean Larson, MD, FAAD

10:50 AM

Clincal Pearls

Dirk Michael Elston, MD, FAAD

11:25 AM

Practical Office Pearls

Stephen P. Stone, MD, FAAD

11:50 AM

Q&A and pearls from the audience

DIRECTOR

Stephen P. Stone, MD, FAAD

Stephen P. Stone, MD, FAAD

SPEAKERS

Dirk Michael Elston, MD, FAAD

Dirk Michael Elston, MD, FAAD

Rebecca Jean Larson, MD, FAAD

Rebecca Jean Larson, MD, FAAD

Mark Lebwohl, MD, FAAD

Mark Lebwohl, MD, FAAD

Morgan Wilson, MD, FAAD

Morgan Wilson, MD, FAAD

HANDOUTS

Login to view handouts

DISCLOSURES

Dirk Michael Elston, MD, FAAD

No financial relationships exist with ineligible companies.

Rebecca Jean Larson, MD, FAAD

No financial relationships exist with ineligible companies.

Mark Lebwohl, MD, FAAD

AbbVie – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Added Health – Consultant (1099 relationship)(Honoraria); Aikium – Consultant (1099 relationship)(Honoraria); Almirall – Consultant(Honoraria); AltruBio Inc. – Consultant(Honoraria); Alumis – Consultant (1099 relationship)(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Honoraria); Atomwise – Consultant(Honoraria); Avotres, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol Myers Squibb – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Consultant(Honoraria); Celltrion – Consultant(Honoraria); Clexio Biosciences, Ltd – Investigator(Grants/Research Funding); CoreEvitas, LLC – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); Dermsquared – Consultant (1099 relationship)(Honoraria); Edesa Biotech – Consultant (1099 relationship)(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Evommune, Inc. – Consultant(Honoraria); Facilitation of International Dermatology Education – Consultant(Honoraria); Forte Biosciences – Consultant(Honoraria); Galderma – Consultant(Honoraria); Genentech, Inc. – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Inozyme Pharma – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); Leo Pharma A/S – Consultant(Honoraria); Mayne Pharma Group – Consultant (1099 relationship)(Honoraria); Meiji Seika Pharma Co., Ltd – Consultant(Honoraria); Mindera – Consultant(Honoraria); Mirum Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); New York College of Podiatric Medicine – Speaker/Faculty Education(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Revolo Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Seanergy Maritime Holdings Corp. – Consultant(Honoraria); Strata Skin Sciences – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Teva Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Trevi Therapeutics – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Consultant(Honoraria);

Stephen P. Stone, MD, FAAD

Abbott Laboratories – Stockholder(Other Financial Benefit); AbbVie – Stockholder Public Company(No Compensation Received); Acuderm, Inc. – Board of Directors(No Compensation Received), Stockholder(No Compensation Received); Becton Dickinson – Stockholder(Other Financial Benefit); Johnson & Johnson Consumer Products Company – Stockholder(Other Financial Benefit); Pfizer Inc. – Stockholder(Other Financial Benefit); Stryker Corporation – Stockholder(Other Financial Benefit);

Morgan Wilson, MD, FAAD

No financial relationships exist with ineligible companies.